Reverse switching from the biosimilar SB2 to the originator infliximab in previously switched patients with inflammatory bowel diseases: results of a prospective long-term cohort study.
- DOI
- 10.1177/17562848241301887
- Published
- 2024
- Container
- Therapeutic advances in gastroenterology
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1177/17562848241301887,
title = {Reverse switching from the biosimilar SB2 to the originator infliximab in previously switched patients with inflammatory bowel diseases: results of a prospective long-term cohort study.},
author = {Fischer S and Donhauser M and Cohnen S and Fietkau K and Vetter M and Grübel-Liehr M and Dietrich P and Rath T and Wilfer A and Sologub L and Krebs S and Dörje F and Nagore D and Meyer S and Neurath MF and Atreya R},
year = {2024},
journal = {Therapeutic advances in gastroenterology},
doi = {10.1177/17562848241301887},
url = {https://doi.org/10.1177/17562848241301887}
}RIS
TY - JOUR TI - Reverse switching from the biosimilar SB2 to the originator infliximab in previously switched patients with inflammatory bowel diseases: results of a prospective long-term cohort study. AU - Fischer S AU - Donhauser M AU - Cohnen S AU - Fietkau K AU - Vetter M AU - Grübel-Liehr M AU - Dietrich P AU - Rath T AU - Wilfer A AU - Sologub L AU - Krebs S AU - Dörje F AU - Nagore D AU - Meyer S AU - Neurath MF AU - Atreya R PY - 2024 JO - Therapeutic advances in gastroenterology DO - 10.1177/17562848241301887 UR - https://doi.org/10.1177/17562848241301887 ER -
APA
S, F., M, D., S, C., K, F., M, V., M, G., P, D., T, R., A, W., L, S., S, K., F, D., D, N., S, M., MF, N., & R, A. (2024). Reverse switching from the biosimilar SB2 to the originator infliximab in previously switched patients with inflammatory bowel diseases: results of a prospective long-term cohort study.. Therapeutic advances in gastroenterology. https://doi.org/10.1177/17562848241301887
Source records
- pubmed · retrieved 2026-09-26T13:32:19.265Z